InvestorsHub Logo
Followers 20
Posts 5129
Boards Moderated 0
Alias Born 01/04/2012

Re: silvr_surfr post# 14288

Tuesday, 05/23/2023 7:39:36 PM

Tuesday, May 23, 2023 7:39:36 PM

Post# of 14475
Slivr, hopefully so. I agree ANI's stake in CG oncology has been diuted but it does look like ANIP may get milestone and royalty payments.

BioSante took a 19.9% stake in Cold Genesys and will get milestones and royalties.

BioSante Pharmaceuticals granted Cold Genesys exclusive, worldwide rights to its oncolytic virus technology in exchange for a 19.9% ownership position in the firm and $95,000 in cash. The deal also covers Phase I CG0070, a replication-competent adenovirus that is being investigated for treatment of superficial bladder cancer. BioSante is also eligible to receive future milestone and royalty payments.

Cold Genesys Buys BioSante’s Oncolytic Virus Technology

I think Merck will end up taking it to market. CG0070 is currently paired with Keytruda in a phase 2 trial

Personally, I think some of the cash will be used to in-licence Nuray Chemicals patent for
Dosage forms of tafamidis and its pharmaceutically acceptable salt thereof. Pfizer's VYNDAQEL franchise brought $686 million last quarter . I see Novitium filing a505(b)(2) as a possibility. After all Samy Shanmugam was the lead inventor in the patent which is set to expire in November 2041.

Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ANIP News